Commentary: Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer

RIPOLL, GISELLE V.; PIFANO, MARINA; GARONA, JUAN; ALONSO, DANIEL F.

Frontiers in Oncology

Frontiers Media S.A.

Año: 2020 vol. 9

Prostate cancer patients managed with androgen-deprivation therapy usually recur after a few years and the disease gradually becomes castration-resistant prostate cancer (CRPC). The role of tumor cell plasticity, including processes such as transdifferentiation and epithelial-mesenchymal transition, is pivotal in the development of androgen receptor (AR)-indifferent tumor variants. Cell plasticity may allow CRPC progression and metastasis by favoring reactivation of AR signaling as a result of different mechanisms of transcriptome reprogramming. Interestingly, dissection of such mechanisms can lead to the identification of novel vulnerabilities of aggressive tumor cells that can be targeted therapeutically.